A diode-end-pumped Nd：YAG dual-wavelength laser operating at 1319 and 1338 nm is demonstrated. The maximum average output power of the quasi-continuous wave linearly polarized dual-wavelength laser is obtained to be ...A diode-end-pumped Nd：YAG dual-wavelength laser operating at 1319 and 1338 nm is demonstrated. The maximum average output power of the quasi-continuous wave linearly polarized dual-wavelength laser is obtained to be 2.1 W at a repetition rate of 50 kHz with an output power instability of less than 0.38% and beam quality factor M^2 of 1.45. Using the two lines, the highly coherent and narrow linewidth terahertz radiation of 3.23 THz can be generated in an organic 4-N, N-dimethylamino-methyl-stilbazolium tosylate （DAST） crystal. Meanwhile, the multi-wavelength red laser at 659.5, 664 and 669 nm is generated by frequency doubling and sum frequency processes in a lithium triborate （LBO） crystal. The average red laser output power is enhanced up to 1.625 W at a repetition rate of 15 kHz with an output power instability of better than 0.53% and beam quality factor M^2 of 6.05. Using the three lines, it is possible to generate the multi-wavelength THz radiation of 3.3, 3.43 and 6.73 THz in an appropriate difference frequency crystal.展开更多
The output characteristics of a narrow linewidth, no-gain competition, dual-wavelength solid-state laser using an intra-cavity pumped method are reported. This system consists of an intra-cavity pumped Nd:YVO4 laser e...The output characteristics of a narrow linewidth, no-gain competition, dual-wavelength solid-state laser using an intra-cavity pumped method are reported. This system consists of an intra-cavity pumped Nd:YVO4 laser emitting at 1064 nm, using a 912 nm Nd:GdVO4 laser. A Fabry-Perot etalon is used to compress the linewidth that located at the common cavity of 912 nm and 1064 nm laser. Theoretical analysis and experimental verification were carried out. When the pump power is 32.8 W, the output of 912 nm and 1064 nm theoretical value is 0.036 W and 0.046 W, and the experimental value is 0.017 W and 0.016 W, respectively. The change trend of the theoretical simulated output power value was the same as the actual measured value in the experiment. In addition to this, the experimental measurement shows when the etalon with an angle of 15?, corresponding minimum linewidths were 0.284 nm and 0.627 nm, respectively.展开更多
Proton pump inhibitors often are prescribed in combination with clopidogrel to decrease risk of gastrointestinal bleeding after acute coronary syndrome. Clopidogrel is a prodrug that has to be metabolized in the liver...Proton pump inhibitors often are prescribed in combination with clopidogrel to decrease risk of gastrointestinal bleeding after acute coronary syndrome. Clopidogrel is a prodrug that has to be metabolized in the liver to generate the active metabolite. Both medications are metabolized largely by the CYP2C19 enzyme;therefore, concerns exist that a drug-drug interaction during concomitant treatment with clopidogrel and a proton pump inhibitor may result in reduction of platelet inhibition. We have reviewed observational and randomized control studies that have evaluated the potential influence of proton pump inhibitors on the platelet inhibitory effect of clopidogrel, along with cardiovascular outcomes. We also have summarized regulatory and academic guidelines for treatment of patients in which concomitant therapy with clopidogrel and proton pump inhibitors may be indicated. Confounding issues, including differential effects of individual proton pump inhibitors on the pharmacodynamics of clopidogrel and variation in clopidogrel metabolism mediated by CYP2C19 gene polymorphisms, also are discussed.展开更多
基金supported by the National Basic Research Program of China (Grant No 2007CB310403)the Tianjin Municipal Primary application and Frontier Technology Research Plan,China (Grant No 07JCYBJC06200)
文摘A diode-end-pumped Nd：YAG dual-wavelength laser operating at 1319 and 1338 nm is demonstrated. The maximum average output power of the quasi-continuous wave linearly polarized dual-wavelength laser is obtained to be 2.1 W at a repetition rate of 50 kHz with an output power instability of less than 0.38% and beam quality factor M^2 of 1.45. Using the two lines, the highly coherent and narrow linewidth terahertz radiation of 3.23 THz can be generated in an organic 4-N, N-dimethylamino-methyl-stilbazolium tosylate （DAST） crystal. Meanwhile, the multi-wavelength red laser at 659.5, 664 and 669 nm is generated by frequency doubling and sum frequency processes in a lithium triborate （LBO） crystal. The average red laser output power is enhanced up to 1.625 W at a repetition rate of 15 kHz with an output power instability of better than 0.53% and beam quality factor M^2 of 6.05. Using the three lines, it is possible to generate the multi-wavelength THz radiation of 3.3, 3.43 and 6.73 THz in an appropriate difference frequency crystal.
文摘The output characteristics of a narrow linewidth, no-gain competition, dual-wavelength solid-state laser using an intra-cavity pumped method are reported. This system consists of an intra-cavity pumped Nd:YVO4 laser emitting at 1064 nm, using a 912 nm Nd:GdVO4 laser. A Fabry-Perot etalon is used to compress the linewidth that located at the common cavity of 912 nm and 1064 nm laser. Theoretical analysis and experimental verification were carried out. When the pump power is 32.8 W, the output of 912 nm and 1064 nm theoretical value is 0.036 W and 0.046 W, and the experimental value is 0.017 W and 0.016 W, respectively. The change trend of the theoretical simulated output power value was the same as the actual measured value in the experiment. In addition to this, the experimental measurement shows when the etalon with an angle of 15?, corresponding minimum linewidths were 0.284 nm and 0.627 nm, respectively.
文摘Proton pump inhibitors often are prescribed in combination with clopidogrel to decrease risk of gastrointestinal bleeding after acute coronary syndrome. Clopidogrel is a prodrug that has to be metabolized in the liver to generate the active metabolite. Both medications are metabolized largely by the CYP2C19 enzyme;therefore, concerns exist that a drug-drug interaction during concomitant treatment with clopidogrel and a proton pump inhibitor may result in reduction of platelet inhibition. We have reviewed observational and randomized control studies that have evaluated the potential influence of proton pump inhibitors on the platelet inhibitory effect of clopidogrel, along with cardiovascular outcomes. We also have summarized regulatory and academic guidelines for treatment of patients in which concomitant therapy with clopidogrel and proton pump inhibitors may be indicated. Confounding issues, including differential effects of individual proton pump inhibitors on the pharmacodynamics of clopidogrel and variation in clopidogrel metabolism mediated by CYP2C19 gene polymorphisms, also are discussed.
